SEC Form 4
City Therapeutics, Inc. (CTY) insider trading
In the 12 months to Oct 26, 2026, 2 CTY insiders reported open-market purchases of $6.1M across 2 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $6.1M
- 2 filings
Who traded CTY, and when
- Purchase
CTY daily close from Oct 16, 2026 to Oct 26, 2026, between $20.43 and $22.40, last $21.01. 0 sale and 2 purchase filings by 2 insiders, marked at their filing dates. Keith Crandell, 10% owner: bought $3.1M across 1 filing, first filed Oct 19, 2026, last Oct 19, 2026. Robert Nelsen, Director: bought $3.1M across 1 filing, first filed Oct 19, 2026, last Oct 19, 2026.
Largest mark · tap a row for others
Keith Crandell · 10% owner
Purchase $3,060,000
170,000 shares at $18.00 avg
Filed Oct 19, 2026
Close on filing date $21.46
Keith Crandell · 10% owner
10% owner
$3.1M boughtRobert Nelsen · Director
Director
$3.1M boughtOpen-market trades
2 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Keith Crandell | 10% owner | — | $3.1M | 1 | — | |
| Robert Nelsen | Director | — | $3.1M | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Robert Nelsen Director | Purchase | 170,000 | $18.00 | $3.1M | 13,692,507 | |
traded | Keith Crandell 10% owner | Purchase | 170,000 | $18.00 | $3.1M | 13,692,507 |
GET /stocks/filings/vX/form-4?tickers=CTY&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"CTY"
],
"issuer_cik": "0002143850",
"owner_cik": "0001219039",
"accession_number": "0001104659-26-116966",
"form_type": "4",
"filing_date": "2026-10-19",
"period_of_report": "2026-10-19",
"issuer_name": "CITY THERAPEUTICS, INC.",
"issuer_trading_symbol": "CTY",
"owner_name": "CRANDELL KEITH",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-19",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 170000,
"transaction_price_per_share": 18,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 13692507,
"transaction_value": 3060000,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "By ARCH Venture Fund XII, L.P.",
"footnotes": [
{
"id": "F2",
"description": "Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Mr. Nelsen serves on the board of directors of the Issuer and is filing his own Form 4 separately."
}
]
},
{
"tickers": [
"CTY"
],
"issuer_cik": "0002143850",
"owner_cik": "0001979765",
"accession_number": "0001104659-26-116966",
"form_type": "4",
"filing_date": "2026-10-19",
"period_of_report": "2026-10-19",
"issuer_name": "CITY THERAPEUTICS, INC.",
"issuer_trading_symbol": "CTY",
"owner_name": "ARCH Venture Partners XII, L.P.",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-19",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 170000,
"transaction_price_per_share": 18,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 13692507,
"transaction_value": 3060000,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "By ARCH Venture Fund XII, L.P.",
"footnotes": [
{
"id": "F2",
"description": "Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Mr. Nelsen serves on the board of directors of the Issuer and is filing his own Form 4 separately."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 7 records
- Other7 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has City Therapeutics, Inc.'s CEO sold stock?
No. Andrew C. Orth (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is CTY’s insider data?
These are CTY Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track CTY insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for CTY every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.